RxDoctor Payments Data

John Jones, MD

Urology · Casper, WYNPI 1275592024

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.1% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations.

$1,933in general payments, 2019–2025

Across 86 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$289
  • Johnson & Johnson$243
  • Astellas Pharma US Inc$232
  • Sumitomo Pharma America, Inc.$226
  • Caldera Medical, Inc$163
  • Coloplast$103
  • plus $677 from 16 others

What the payments were for

  • Food & beverage$1,74190%
  • Education$19110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$365,403
Medicare patients
826
Services billed
6,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide29$407,874
XtandiEnzalutamide19$273,594
OrgovyxRelugolix98$253,471
MyrbetriqMirabegron121$78,056
Abiraterone Acetate13$29,250
Tamsulosin Hcl729$16,670
Finasteride501$8,573
Tolterodine Tartrate ErTolterodine Tartrate62$6,781
Estradiol53$6,138
Oxybutynin Chloride ErOxybutynin Chloride230$5,875
Solifenacin Succinate144$5,555
Trimethoprim55$3,754
Trospium Chloride43$3,060
Imipramine Hcl109$3,041
Testosterone Cypionate48$2,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$243$407,87429 claims
Astellas Pharma US IncXtandi, Myrbetriq$232$351,650140 claims
Sumitomo Pharma America, Inc.Orgovyx$226$253,47198 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other urology in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →